SummaryHeparin therapy for children undergoing cardiopulmonary bypass (CPB) is monitored in the operating room by automated whole blood activated clotting times (ACT). For many years our institution used Hemochron (HC) ACT machines but changed to HemoTec (HT) ACT machines because they required a smaller blood sample and provided results in duplicate. When HemoTec ACT machines were introduced at our institution, the surgical team was concerned that increased amounts of heparin were being administered to our patients during CPB. This study was conducted to investigate the potential mechanisms responsible for these clinical observations. First, we compared ACT values on ex vivo blood samples from 20 consecutive pediatric patients (6 samples each) during CPB. The HC ACT values were significantly and systematically increased over HT ACT values (HC: 750 ± 40 vs HT: 418 ± 26, Mean ± SEM, p <0.01). 94% of all HC ACT values were above 450 s compared to only 27% of HT ACT values. If HT ACT values had been used for patient monitoring, all patients would have received more heparin to achieve ACT values above 450 s. The two machines reported similar ACT values when heparin was added in vitro to whole blood (0.1-5.0 units/ml), (HC: Y = 98X + 104, r2 = 0.93 HT: Y = 82X + 109, r2 = 0.94). Heparin concentrations in our patients following a bolus of 300 U/kg of heparin, but prior to CPB were 3.2 ± 0.07 units/ml. Following the initiation of CPB, heparin concentrations decreased to 1.3 ± 0.05, reflecting, in part, hemodilution by the pump prime (1 U of heparin/ml). In contrast to the in vitro results, there was no relationship between ACT values measured by either machine and plasma heparin concentrations in ex vivo samples. Finally, plasma concentrations of 8 coagulation proteins measured prior to CPB and following CPB were decreased by 27-55%, predominantly reflecting the final dilution by CPB. In conclusion: 1) HT and HC machines cannot be used interchangeably in pediatric patients without risk of altering clinical practice in an uncontrolled fashion; and 2) ACT values from children on CPB correlate poorly with heparin concentrations, likely due to hemodilution. Optimal use of anticoagulant therapy during CPB in children requires further study in clinical trials and ongoing quality control.

Objetivo: realizar la traducción y adaptación transcultural de la versión original del Índice de Barthel (IB) al español, en su versión argentina. Materiales y método: Se formaron dos equipos que trabajaron de manera independiente. Uno realizó una traducción por comité y el otro una traducción inversa. Se compararon y conciliaron ambas versiones y se formó una versión pre-final. Dicha versión fue presentada a un focus group. El mismo puntuó cada ítem del IB con una escala de Likert, emitiendo opiniones al respecto. Resultados: Se realizó la traducción y adaptación transcultural del Índice de Barthel siguiendo las directrices de la International Test Commission (2017). Se modificaron los ítems correspondientes y de esta manera se llegó a la versión final del IB en español, en su versión argentina. Conclusión: Luego de realizada la traducción y adaptación transcultural del IB, queda conformada su versión argentina en español.